- Home
- INCR vs ENTX Comparison
INCR vs ENTX Comparison
Compare INCR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ENTX
- Stock Information
- Founded
- INCR 1994
- ENTX 2010
- Country
- INCR Israel
- ENTX Israel
- Employees
- INCR N/A
- ENTX N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INCR Health Care
- ENTX Health Care
- Exchange
- INCR Nasdaq
- ENTX Nasdaq
- Market Cap
- INCR 88.9M
- ENTX 86.3M
- IPO Year
- INCR N/A
- ENTX 2018
- Fundamental
- Price
- INCR $1.63
- ENTX $2.00
- Analyst Decision
- INCR
- ENTX Strong Buy
- Analyst Count
- INCR 0
- ENTX 1
- Target Price
- INCR N/A
- ENTX $10.00
- AVG Volume (30 Days)
- INCR 32.8K
- ENTX 67.6K
- Earning Date
- INCR 08-28-2025
- ENTX 11-07-2025
- Dividend Yield
- INCR N/A
- ENTX N/A
- EPS Growth
- INCR N/A
- ENTX N/A
- EPS
- INCR N/A
- ENTX N/A
- Revenue
- INCR $65,575,323.00
- ENTX $166,000.00
- Revenue This Year
- INCR $69.54
- ENTX N/A
- Revenue Next Year
- INCR $41.75
- ENTX N/A
- P/E Ratio
- INCR N/A
- ENTX N/A
- Revenue Growth
- INCR N/A
- ENTX 191.23
- 52 Week Low
- INCR $1.17
- ENTX $1.50
- 52 Week High
- INCR $2.07
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- INCR 53.29
- ENTX 51.82
- Support Level
- INCR $1.57
- ENTX $2.00
- Resistance Level
- INCR $1.65
- ENTX $2.22
- Average True Range (ATR)
- INCR 0.07
- ENTX 0.11
- MACD
- INCR -0.01
- ENTX 0.01
- Stochastic Oscillator
- INCR 57.50
- ENTX 47.62
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.